Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Inclusion Criteria: * Locally advanced/unresectable or metastatic breast cancer * Eighteen years of age or above * Able to understand and sign an informed consent (or have a legal representative who is able to do so) * Measurable disease according to RECIST v1.1 * ECOG Performance Score of 0 or 1 * Adequate bone marrow, hepatic, renal and cardiac function * Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-302 Exclusion Criteria: * Patients for whom potentially curative anticancer therapy is available * Active infection or fever \> 38.5°C during screening visits or on the first scheduled day of dosing * Symptomatic CNS disease * Known hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodies * Received other recent antitumor therapy * Pregnant or breast feeding * Patients with any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results